AMRN
Amarin CorpAMRN
AMRN
About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Employees: 275
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
360% more call options, than puts
Call options by funds: $276K | Put options by funds: $60K
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
1.3% more ownership
Funds ownership: 15.92% [Q3] → 17.22% (+1.3%) [Q4]
1% more funds holding
Funds holding: 158 [Q3] → 160 (+2) [Q4]
16% less capital invested
Capital invested by funds: $41.1M [Q3] → $34.4M (-$6.66M) [Q4]
39% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 46
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
23%
downside
Avg. target
$7
23%
downside
High target
$7
23%
downside
1 analyst rating
0 positive
0%
0 neutral
0%
1 negative
100%
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 23%downside $7 | Sell Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 3 articles about AMRN published over the past 30 days
Negative
Benzinga
4 days ago
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Monday.
Neutral
GlobeNewsWire
1 week ago
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company's previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change").
Neutral
GlobeNewsWire
1 week ago
Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately.
Neutral
Business Wire
1 month ago
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the “Board”) 88 Harcourt Street Dublin 2, Ireland.
Neutral
GlobeNewsWire
1 month ago
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL.
![New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo](https://wsr-news.imgdelivr.io/8XNJYGFA.jpg?w=640&h=360)
Neutral
Seeking Alpha
1 month ago
Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Neutral
GlobeNewsWire
1 month ago
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprotein Cholesterol (
Neutral
GlobeNewsWire
1 month ago
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET.
Neutral
GlobeNewsWire
4 months ago
Amarin Receives National Reimbursement for VAZKEPA® in Italy
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
Neutral
GlobeNewsWire
4 months ago
Amarin Appoints Peter Fishman Chief Financial Officer
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company
Charts implemented using Lightweight Charts™